{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"7200","value":"500"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"5100","value":"200"}]}],"title":"BDNF"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"226.00","value":"7.5"},{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"71.00","value":"0.00"}]}],"title":"ITAC"}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"description":"Serum levels were determined for 38 circulating proteins. Selected values showing statistically significant differences compared with baseline are reported here. ITAC (Interferon-inducible T-cell α chemoattractant) level in LDAC alone arm at Cycle 1/Day 10 exhibited non-significant change from baseline but similar trends as in Glasdegib 100 mg+LDAC arm.","dispersionType":"Full Range","groups":[{"description":"Participants received oral doses of glasdegib tablets 100 mg QD in 28-day cycles on a continuous basis, starting on Day 1 of Cycle 1. LDAC was given at a dose of 20 mg subcutaneously BID on Days 1-10 of the 28 day cycles.","id":"OG000","title":"Phase 2 Unfit: Glasdegib 100 mg + LDAC"},{"description":"Participants received LDAC subcutaneously at a dose of 20 mg BID on Days 1-10 of the 28 day cycles.","id":"OG001","title":"Phase 2 Unfit: LDAC Alone"}],"paramType":"MEDIAN","populationDescription":"PD analysis set: all enrolled participants in the Phase 2 Unfit portion who received at least 1 dose of glasdegib, and had at least 1 PD parameter from the corresponding assay sample with a baseline and an adequate post treatment assessment.","reportingStatus":"POSTED","timeFrame":"Cycle 1/Day 10, Pre-dose","title":"Serum Levels of Circulating Protein Analytes at Phase 2 Unfit - Cycle 1/Day 10","type":"SECONDARY","unitOfMeasure":"pg/mL"}